One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade.
Xincheng XuZihong ChenCaroline R BartmanXi XingKellen OlszewskiJoshua D RabinowitzPublished in: bioRxiv : the preprint server for biology (2023)
Checkpoint blockade has revolutionized cancer therapy. Durable tumor control, however, is achieved in only a minority of patients. We show that the efficacy of anti-PD-1 blockade can be enhanced by metabolic supplementation with one-carbon donors. Such donors support nucleotide synthesis in tumor-infiltrating T cells and merit future clinical evaluation.